Effect of atorvastatin on expression of TLR4 and NF-κB p65 in atherosclerotic rabbits

Asian Pacific Journal of Tropical Medicine

Volumn 6, Issue 6, 2013, Pages 493-496

  Shen, Ding Zhu ^a   Xin, San Li ^a   Chen, Chuan ^a   Liu, Te ^a  

^a LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Atherosclerosis; Atorvastatin; NF B p65; TLR4

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IMMUNE INJURY; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; STAINING; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEPTANOIC ACIDS; HISTOCYTOCHEMISTRY; MALE; PYRROLES; RABBITS; RANDOM ALLOCATION; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA;

EID: 84885630547     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(13)60081-4     Document Type: Article

References (12)

1. Daviglus ML, Talavera GA, Avilés-Santa ML, Allison M, Cai J, Criqui MH, et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among hispanic/latino individuals of diverse backgrounds in the United States. JAMA 2012, 308(17):1775-1784.
2. Athyros VG, Mikhailidis DP Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 fatty acid ethyl esters. Open Cardiovasc Med J 2012, 6:122-125.
3. Traditional Chinese medicine pharmacology experimental methodology 2006, 423. Shanghai science and technology publishing house, Shanghai.
4. Pina-Canseco Mdel S, Píez-Arenas A, Massó F, Pérez-Campos E, Martínez-Cruz R, Herníndez-Cruz P, et al. Protein C activation peptide inhibits the expression of ICAM-1, VCAM-1, and interleukin-8 induced by TNF-a in human dermal microvascular endothelial cells. Folia Histochem Cytobiol 2012, 50(3):407-413.
5. Müller II, Müller KA, Scho-nleber H, Karathanos A, Schneider M, Jorbenadze R, et al. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. PLoS One 2012, 7(6):e38376.
6. Eshtehardi P, McDaniel MC, Dhawan SS, Binongo JN, Krishnan SK, Golub L, et al. Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling, and microvascular function. J Invasive Cardiol 2012, 24(10):522-529.
7. Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CM Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) [from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) study]. Am J Cardiol 2009, 103(8):1056-1060.
8. Upaganlawar A, Patel V, Balaraman R Tomato lycopene attenuates myocardial infarction induced by isoproterenol: Electrocardiographic, biochemical and anti-apoptotic study. Asian Pac J Trop Biomed 2012, 2(5):345-351.
9. Kumar A, Biswas UK, Nagtilak S, Ramiah S Lipid ratio useful indicator in predicting risk of myocardial infarction in elderly normolipidemic patients: a report from a multi center study. Asian Pac J Trop Dis 2011, 1(2):123-126.
10. Pina-Canseco Mdel S, Píez-Arenas A, Massó F Protein C activation peptide inhibits the expression of ICAM-1, VCAM-1, and interleukin-8 induced by TNF-a in human dermal microvascular endothelial cells. Folia Histochem Cytobiol 2012, 50(3):407-413.
11. Taur DJ, Patil RY Some medicinal plants with antiasthmatic potential: a current status. Asian Pac J Trop Biomed 2011, 1(5):413-418.
12. Barofio M, Crimi E, Brusasco V Airway Smooth muscle as a model for new investigative drugs in asthma. Ther Adv Respir Dis 2008, 2(3):129-139.